Shanghai Pharma Stock Continues Fall Despite Denial Of Securities Investigation
This article was originally published in PharmAsia News
Refuting an investigation and M&A malfeasance hasn't prevented shares from tumbling for Shanghai Pharma, which has Pfizer Inc. as a cornerstone investor.
You may also be interested in...
SHANGHAI - Shanghai Pharmaceutical Holdings Co. Ltd is set for what could be the largest IPO by a pharmaceutical company ever, surpassing Ostuka Holding's $2.4 billion IPO from last year
Regulators in Southeast Asia are working to tighten bribery and corruption enforcement as part of a broader push ahead of an Association of Southeast Asian Nations trade pact in 2015 for greater transparency in pharmaceuticals.
The first commercial implant for St. Jude’s Allure Quadra in Hong Kong is a sign for optimism for its pacemaker business after last year’s disappointments in Japan.